We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+25.66%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.77B
AUM Growth
+$373M
Cap. Flow
-$163M
Cap. Flow %
-2.41%
Top 10 Hldgs %
45.13%
Holding
79
New
15
Increased
25
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$108M
2
IMTX icon
Immatics
IMTX
+$99.3M
3
MRUS
Merus
MRUS
+$70.4M
4
DYN icon
Dyne Therapeutics
DYN
+$69.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$63.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$398M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$314M
3
CLDX icon
Celldex Therapeutics
CLDX
+$137M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$98.5M
5
VCEL icon
Vericel Corp
VCEL
+$70.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$357M
$477M 7.03%
17,687,772
– –
IMCR icon
2
Immunocore
IMCR
$1.78B
$391M 5.78%
6,019,641
-76,746
-1% -$5.27M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.3B
$359M 5.29%
4,492,679
+3,083
+0.1% +$259K
RARE icon
4
Ultragenyx Pharmaceutical
RARE
$2.66B
$331M 4.88%
7,087,115
+200,029
+3% +$9.44M
BRKR icon
5
Bruker
BRKR
$9.23B
$314M 4.64%
3,344,095
– –
ARGX icon
6
argenx
ARGX
$56B
$263M 3.88%
667,195
– –
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.35B
$256M 3.77%
13,829,315
+2,575,764
+23% +$63.8M
NTRA icon
8
Natera
NTRA
$37.3B
$237M 3.5%
2,593,323
– –
PTCT icon
9
PTC Therapeutics
PTCT
$6.36B
$216M 3.19%
7,423,970
– –
MASI
10
DELISTED
Masimo
MASI
$215M 3.17%
1,462,400
– –
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$203M 3%
7,970,269
+1,280,480
+19% +$20.1M
MRUS
12
DELISTED
Merus
MRUS
$185M 2.73%
4,109,393
+1,735,768
+73% +$70.4M
CYTK icon
13
Cytokinetics
CYTK
$11B
$177M 2.61%
2,525,080
– –
APGE icon
14
Apogee Therapeutics
APGE
$10.2B
$164M 2.42%
2,467,591
+325,000
+15% +$14.2M
ALKS icon
15
Alkermes
ALKS
$8.81B
$164M 2.42%
6,054,280
+2,152,757
+55% +$61.1M
PTGX icon
16
Protagonist Therapeutics
PTGX
$8.88B
$154M 2.27%
5,315,514
– –
PEN icon
17
Penumbra
PEN
$12.6B
$151M 2.23%
675,888
+13,224
+2% +$3.27M
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$149M 2.19%
8,798,558
+1,850,640
+27% +$27.6M
AKRO
19
DELISTED
Akero Therapeutics
AKRO
$137M 2.03%
5,431,985
+1,839,226
+51% +$44.2M
ESTA icon
20
Establishment Labs
ESTA
$2.71B
$136M 2.01%
2,675,703
+181,565
+7% +$7.29M
ARVN icon
21
Arvinas
ARVN
$534M
$136M 2.01%
3,297,897
-915,586
-22% -$40M
TARS icon
22
Tarsus Pharmaceuticals
TARS
$2.67B
$119M 1.76%
3,272,341
+120,000
+4% +$3.53M
SYK icon
23
Stryker
SYK
$129B
$115M 1.7%
+321,000
New +$108M
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$12.8B
$106M 1.57%
397,047
-418,144
-51% -$98.5M
IMTX icon
25
Immatics
IMTX
$1.26B
$105M 1.55%
10,000,000
+8,515,089
+573% +$99.3M
1
2 3 4

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q1 2024 Portfolio in Review

As of Q1 2024, RTW Investments held 79 positions worth $6.77B, up 5.8% from $6.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments's Q1 2024 filing shows 15 new, 25 increased, 7 reduced and 10 closed positions. Its largest new stake was Stryker: 321,000 shares worth $115M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $398M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q1 2024 buy was Stryker: 321,000 shares worth $115M.
  • RTW Investments added most to Immatics in Q1 2024, an estimated $99.3M increase.
  • RTW Investments's biggest Q1 2024 reduction was Madrigal Pharmaceuticals, cutting an estimated $98.5M.
  • RTW Investments fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $398M.
  • RTW Investments's ten largest holdings make up 45% of its $6.77B portfolio in Q1 2024.
  • RTW Investments opened 15 new positions and closed 10 in Q1 2024.
  • RTW Investments's portfolio value rose 5.8% quarter-over-quarter to $6.77B.

Based on RTW Investments's 13F filing for Q1 2024, filed 15 May 2024.